Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis

Liver Transplantation

Volumn 14, Issue 12, 2008, Pages 1766-1777

  Roche, Bruno ^a,b,c   Sebagh, Mylene ^a,b,c   Canfora, Maria Laura ^a   Antonini, Teresa ^a   Roque Afonso, Anne Marie ^a,b,c   Delvart, Valerie ^a   Saliba, Faouzi ^a,b,c   Duclos Vallee, Jean Charles ^a,b,c   Castaing, Denis ^a,b,c   Samuel, Didier ^a,b,c  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VERAFERONPEG; ANTIVIRUS AGENT; INTERFERON;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; REOPERATION; SIDE EFFECT; SURGICAL MORTALITY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS TYPING; DRUG COMBINATION; FOLLOW UP; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58249086156     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21635     Document Type: Article

References (35)

1. Gane EJ, Portmann B, Naoumov N, Smith H, Underhill J, Donaldson P, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334: 815-820.
2. Feray C, Caccamo L, Alexander G, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999;117:619-625.
3. Forman LM, Lewis J, Berlin J, Feldman H, Lucey M. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
4. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
5. Firpi R, Abdelmalek M, Soldevilla-Pico C, Reed A, Hemming A, Howard R, et al. combination of interferon alpha-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002;8: 1000-1006.
6. Shakil AO, Mc Guire B, Crippin J, Teperman L, Demetris A, Conjeevaram, et al. A pilot study of interferon alpha and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002;36:1253-1258.
7. Samuel D, Bizollon T, Feray C, Roche B, Si Ahmed S, Lemonnier C, et al. Interferon alpha-2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;124: 642-650.
8. Wang C, Ko H, Yoshida E, Marra C, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transpl 2006;6:1586-1599.
9. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004;40:669-674.
10. Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006;12:1067-1076.
11. Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams J, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alfa-2b and ribavirin: an open label series. Transplantation 2004;77:190-194.
12. Neff GW, O'Brien C, Cirocco R, Montalbano M, de Medina M, Ruiz P, et al. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. Liver Transpl 2004;10:595-598.
13. Sharma P, Marrero J, Fontana R, Greenson J, Conjeevaram H, Su G, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virological response and dose adherence. Liver Transpl 2007;13:1100-1108.
14. Bizollon T, S Ahmed S, Radenne S, Chevallier M, Chevallier P, Parvaz P, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003;52:283-287.
15. Bahra M, Neumann UP, Jacob D, Langrehr JM, Berg T, Neuhaus R, Neuhaus P. Fibrosis progression in hepatitis C positive liver recipients after sustained virological response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation 2007;83:351-353.
16. Abdelmalek MF, Firpi R, Soldevila-Pico C, Reed A, Hemming A, Liu C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004:10:199-207.
17. Walter T, Dumortier J, Guillaud O, Hervieu V, Scoazec JY, Boillot O. Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center. Liver Transpl 2007; 13:294-301.
18. Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007;132:1746-1756.
19. Picciotto FP, Tritto G, Lanza A, Addario L, De Luca M, Di costanzo G, et al. Sustained virological response to anti-viral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007;46:459-465.
20. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008;8:679-687.
21. Bizollon T, Pradat P, Mabrut JY, Radenne S, Ducerf C, Baulieux J, et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transpl 2007;7:448-453.
22. Neff GW, Montalbano M, O'Brien CB, Nishida S, Safdar K, Bejarano PA, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004;78:1303-1307.
23. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR cooperative study group. Hepatology 1994;20:15-20.
24. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
25. Fernandez I, Meneu JC, Colina F, Garcia I, Munoz R, Castellano G, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12:1805-1812.
26. Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006;6:2348-2355.
27. Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, et al. A randomized study on peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007;46:1009-1017.
28. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008;14:53-58.
29. Walter T, Dumortier J, Guillaud O, Hervieu V, Pailard P, Scoazec JY, Boillot O. Rejection under alpha interferon therapy in liver transplant recipients. Am J Transpl 2007; 7:177-184.
30. Stravitz RT, Shiffman M, Sanyal A, Luketic V, Sterling R, Heuman D, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004;10:850-858.
31. Saab S, Kalmaz D, Gajjar N, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004;10:859-867.
32. Berardi S, Lodato F, Gramenzi A, D'Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007;56: 237-242.
33. Kontorinis N, Agarwal K, Elhajj N, Fiel M, Schiano T. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006;12:827-830.
34. Saab S, Oh M, Ibrahim A, Durazo F, Han S, Yersiz H, et al. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007; 13:1032-1038.
35. Castells L, Vargas V, Allende H, Bilbao I, Lazaro JL, Margarit C, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005;43:53-59.